CompletedPhase 1/2

Use of Ziv Aflibercept in Different Retinal Diseases

Egypt55 participantsStarted 2019-06-01

Plain-language summary

A prospective interventional case series study was conducted on 20 eyes of 20 patients with active myopic choroidal neovascularisation (CNV) ,20 eyes with resistant diabetic macular edema and 15 eyes with non ischaemic central retinal vein occlusion(CRVO) after approval of the Ethical Committee of the Faculty of Medicine, Tanta University . All procedures were carried out under the tenets of the Helsinki Declaration. Written consent was provided by all participants after discussing the procedure, alternative treatment plans, follow-up schedules, and possible benefits and risks.

Who can participate

Age range31 Years – 63 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * The study included treatment naive patients suffering from recently diagnosed active myopic subfoveal or juxtafoveal CNV less than 2 months documented by fundus fluorescein angiography (FFA)and optical coherence tomography (OCT ) , pathological myopia more than 6 D was included . Exclusion Criteria: * Previous intraocular surgery . * Coincident retinal pathology as diabetic retinopathy, retinal vein occlusion . * CNV due to other causes like age related macular degeneration ,angioid streaks,trauma and choroiditis. * Extrafoveal myopic CNV . * Patients received other lines of treatment for CNV like photodynamic therapy ,laser photocoagulation or intravitreal injection of triamcinolone or other anti VEGF(vascular endothelial growth factor) agents. * Known glaucoma , clinical suspicion of glaucoma or IOP(intraocular pressure) more than 20 mmHg. * Prior ocular inflammation. * The presence of retinal degeneration. * Patients who didnot complete 6 months of follow up

What they're measuring

Improvement of BCVA by log MAR(minimum angle of resolution) and reduction of CMT after intravitreal injection

Timeframe: 6 months

Trial details

NCT IDNCT04290195

SponsorAmin El Sayed Nawar

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-12-01